Mutations with benefits – resisting epidemics.

The term “mutation” is a bit loaded, as it implies a defect or deficiency or aberration of some sort. But the value of a particular version of a gene is very much dependent on its context – what might be a defect in one context conveys an advantage in another. And that context means not Read More …

More flu drugs than one

The FDA today cleared a new drug for treating influenza, the first in 20 years. Xofluza (baloxovir) appears to have about the same efficacy as oseltamivir in reducing symptoms of patients with uncomplicated influenza infections. Maybe a little better: From Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents Baloxavir attacks a different target (RNA replication) Read More …